Companies › Verrica Pharmaceuticals
3 active drug programs in 3 registered trials: 3 Phase 3; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VP-102 Cantharidin topical application | – | Phase 3 | Common Warts | Nov 2026 |
| VP-102 (US) / TO-208 (Japan) Cantharidin-based topical treatment | – | Phase 3 | Common Warts | May 2027 |
| Cantharidin (YCANTH [VP-102/TO-208]) Blister-inducing topical agent with vesicant properties | – | Phase 3 | Common Warts (Verruca Vulgaris) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07246590 | VP-102 | Phase 3 | Common Warts | Infectious disease | Nov 2026 |
| NCT07637734 | VP-102 (US) / TO-208 (Japan) | Phase 3 | Common Warts | Infectious disease | May 2027 |
| NCT07457918 | Cantharidin (YCANTH [VP-102/TO-208]) | Phase 3 | Common Warts (Verruca Vulgaris) | Infectious disease | Nov 2027 |
Cash of $11m on 2026-06-30; operating cash outflow about $37m a year; runway about 4 months at that burn, to Oct 2026; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Invivyd Traws Pharma Labo'Life 60 Degrees Pharmaceuticals Lakewood-Amedex
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.